Andrew Aguirre, M.D., Ph.D.
Affiliations: | Dana Farber Cancer Institute, Boston, MA, United States |
Google:
"Andrew Aguirre"Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pelka K, Hofree M, Chen JH, et al. (2021) Spatially organized multicellular immune hubs in human colorectal cancer. Cell |
| Singh H, Perez K, Wolpin BM, et al. (2021) Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101510 |
| Dai C, Rennhack JP, Arnoff TE, et al. (2021) SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Cell Reports. 36: 109443 |
| Cleary JM, Wolpin BM, Dougan SK, et al. (2021) Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Neggers JE, Paolella BR, Asfaw A, et al. (2021) Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Reports. 36: 109367 |
| Neggers JE, Paolella BR, Asfaw A, et al. (2021) Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Reports. 36: 109367 |
| Waters AM, Khatib TO, Papke B, et al. (2021) Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports. 35: 109291 |
| Waters AM, Khatib TO, Papke B, et al. (2021) Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports. 35: 109291 |
| Awad MM, Liu S, Rybkin II, et al. (2021) Acquired Resistance to KRAS Inhibition in Cancer. The New England Journal of Medicine. 384: 2382-2393 |
| Cleary JM, Wang VX, Heist RS, et al. (2021) Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |